Welcome to STN International! Enter x:x

LOGINID:ssspta1600rxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * Welcome to STN International * * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	DEC 08	INPADOC: Legal Status data reloaded
NEWS 5	SEP 29	DISSABS now available on STN
NEWS 6	OCT 10	PCTFULL: Two new display fields added
NEWS 7	OCT 21	BIOSIS file reloaded and enhanced
NEWS 8	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 9	NOV 24	MSDS-CCOHS file reloaded
NEWS 10	DEC 08	CABA reloaded with left truncation
NEWS 11	DEC 08	IMS file names changed
NEWS 12	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 13	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 14	DEC 17	DGENE: Two new display fields added
NEWS 15	DEC 18	BIOTECHNO no longer updated
NEWS 16	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 17	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 18	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 19	DEC 22	ABI-INFORM now available on STN

NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:51:48 ON 13 JAN 2004

=> fil reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:52:00 ON 13 JAN 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2004 HIGHEST RN 636558-22-0
DICTIONARY FILE UPDATES: 11 JAN 2004 HIGHEST RN 636558-22-0

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading 09815362g.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 07:52:13 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   2635 TO ITERATE

 38.0% PROCESSED    1000 ITERATIONS                                  6 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        49622 TO    55778
PROJECTED ANSWERS:              78 TO      554

L2             6 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:52:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  51880 TO ITERATE

100.0% PROCESSED   51880 ITERATIONS                               267 ANSWERS
SEARCH TIME: 00.00.01

L3           267 SEA SSS FUL L1

=> s l3 and caplus/lc
      32498121 CAPLUS/LC
L4          258 L3 AND CAPLUS/LC

=> s l3 not l4
L5            9 L3 NOT L4

=> d l5 1-9
```

L5 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 337534-09-5 REGISTRY
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-, (-)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H20 N2 O2
CI COM
SR CA

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 336103-05-0 REGISTRY
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C20 H23 N3 O2
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 336102-60-4 REGISTRY
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (+)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H21 N3 O2
CI COM
SR CA

Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 336102-58-0 REGISTRY
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H22 N2 O2
CI COM
SR CA

Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 247173-10-0 REGISTRY
CN 1H-Imidazole-4-methanol, .alpha.-(1,1-dimethylethyl)-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H22 N2 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 247173-08-6 REGISTRY
CN 1H-Imidazole-4-methanol, .alpha.-cyclopropyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H18 N2 O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 150560-49-9 REGISTRY
CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C30 H30 N2 O3
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 75601-48-8 REGISTRY
CN Methanone, 1H-imidazol-4-yl[4b,5,6,7,8,8a,9,10-octahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl]-, [4bS-(4b.alpha.,8.alpha.,8a.beta.)]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H30 N2 O
LC STN Files: BEILSTEIN*, SPECINFO
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2004 ACS on STN
RN 75601-29-5 REGISTRY
CN Methanone, [4b,5,6,7,9,10-hexahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl]-1H-imidazol-4-yl-, (4bS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H28 N2 O

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	176.20	176.41

FILE 'CAPLUS' ENTERED AT 07:52:59 ON 13 JAN 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Jan 2004 VOL 140 ISS 3
FILE LAST UPDATED: 12 Jan 2004 (20040112/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4
L6 33 L4

=> d ibib abs hitstr 1-33

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:951005 CAPLUS
DOCUMENT NUMBER: 140:5050
TITLE: Preparation of 4-substituted imidazole-2-thiones and imidazol-2-ones as agonists of alpha-2B and alpha-2C adrenergic receptors
INVENTOR(S): Chow, Ken; Heidelbaugh, Todd; Gil, Daniel; Garst, Michael; Wheeler, Larry A.; Nguyen, Phong X.; Gomez, Dario G.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099795	A1	20031204	WO 2003-US15441	20030516

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-153328 A 20020521
GI



I

AB The title compds. [I; Y in the ring is optional and represents a heteroatom selected from N, O and S with the proviso that the N atom is trivalent, and the O or S atoms are divalent; m = 0, 1; n, p = 0, 1, 2; X = O, S; the dashed lines represent a bond, or absence of bond with the proviso that only one double bond is present in the ring and that two adjoining dashed lines do not both represent a bond; R1-R4 = independently H, (un)substituted Ph, C1-4 alkyl, C3-5 cycloalkyl, CH2CN, CH2SR5, CH2NR6R6, COR5, CH2OR5, OR6, SR6, NR6R6, C2-4 alkenyl or alkynyl, F, Cl, Br, iodo, CF3, cyano, an oxygen double bonded to the ring carbon with the proviso that the adjacent dashed line within the ring represents absence of a bond; R5 = H, OR7, C1-4 alkyl, CF3, C3-6 cycloalkyl, (un)substituted Ph or 5 or 6 membered heteroaryl having 1 to 3 heteroatoms selected from O, S, and N; R6 = H, C1-4 alkyl, allyl, C3-6 cycloalkyl, (un)substituted Ph or 5 or 6 membered heteroaryl having 1 to 3 heteroatoms selected from O, S, and N; R7 = H, C1-4 alkyl, allyl, C3-6 cycloalkyl, (un)substituted phenyl; R1 and R2 or R2 and R3 or R3 and R4 together can form a ring together with the resp. carbons to which each of these is attached; R10 = H, C1-6 or alkyl] are prepd. These compds. possess specific or selective binding activity to .alpha.2B and/or .alpha.2C adrenergic receptors in preference over .alpha.A adrenergic receptors, and as such have no or only minimal cardiovascular and/or sedative activity. They are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviation of conditions which are responsive to treatment by agonists of .alpha.B adrenergic receptors. The diseases and conditions include pain, allodynia, chronic pain, visceral pain, neuropathic pain, corneal pain, glaucoma, elevated intraocular pressure, ischemic neuropathies, neurodegenerative diseases, diarrhea, nasal congestion, muscle spasticity, diuresis, withdrawal syndromes, optic neuropathy, spinal ischemia, stroke, memory and cognition deficits, attention deficit disorder, psychoses, manic disorders, anxiety, depression, hypertension, congestive heart failure, cardiac ischemia, arthritis, spondylitis, gouty arthritis, osteoarthritis, juvenile arthritis, autoimmune diseases, lupus erythematosus, chronic gastrointestinal inflammations, Crohn's disease, gastritis, irritable bowel disease (IBD), functional dyspepsia and ulcerative colitis. For example, 4-(4-methylindan-2-yl)-1,3-dihydroimidazole-2-thione showed agonism activity on .alpha.2B and .alpha.2C adrenergic receptors with EC50 of 3 and 13 nM, resp. and no activity on .alpha.2A adrenergic receptor.

IT **157058-52-1P 628732-24-1P 628732-25-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)

RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 628732-24-1 CAPLUS
CN Acetonitrile, [3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-1(2H)-naphthalenylidene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 628732-25-2 CAPLUS
CN Acetonitrile, [3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-1(2H)-naphthalenylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

IT **628730-35-8P 628730-36-9P**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)

RN 628730-35-8 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

RN 628730-36-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

IT **423773-40-4P 628730-38-1P 628730-40-5P 628730-44-9P 628730-45-0P 628730-46-1P 628730-47-2P 628730-48-3P 628730-49-4P 628730-50-7P 628730-51-8P 628730-52-9P 628730-53-0P 628730-88-1P 628731-16-8P 628731-17-9P 628731-32-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)

RN 423773-40-4 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

RN 628730-38-1 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-4-methyl- (9CI) (CA INDEX NAME)

RN 628730-40-5 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-6-hydroxy- (9CI) (CA INDEX NAME)

RN 628730-44-9 CAPLUS
CN 2H-Imidazole-2-thione, 1,3-dihydro-4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 628730-45-0 CAPLUS
CN 2H-Imidazole-2-thione, 1,3-dihydro-4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 628730-46-1 CAPLUS
CN 2H-Imidazole-2-thione, 1,3-dihydro-4-[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 628730-47-2 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4,5,6,7,8-hexahydro- (9CI) (CA INDEX NAME)



RN 628730-48-3 CAPLUS
CN 2H-Imidazole-2-thione, 1,3-dihydro-4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 628730-53-0 CAPLUS
CN 1(2H)-Naphthalenone, 2-{(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl}-6-fluoro-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 628730-88-1 CAPLUS
CN 1(2H)-Naphthalenone, 8-chloro-2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 628731-16-8 CAPLUS
CN Acetonitrile, [2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-1(2H)-naphthalenylidene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 628731-17-9 CAPLUS
CN Acetonitrile, [2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-1(2H)-naphthalenylidene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 628730-49-4 CAPLUS
CN 2H-Imidazole-2-thione, 1,3-dihydro-4-[[(2R)-1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 628730-50-7 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-8-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 628730-51-8 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-8-methyl- (9CI) (CA INDEX NAME)



RN 628730-52-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-8-fluoro-3,4-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 628731-32-8 CAPLUS
CN 2H-Imidazol-2-one, 1,3-dihydro-4-[(1,2,3,4-tetrahydro-1-oxo-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



IT **226571-13-7P**
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
RN 226571-13-7 CAPLUS
CN 1H-Imidazole, 4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **157058-44-1P 226571-02-4P 226571-05-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-02-4 CAPLUS

L6 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



IT **628731-55-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of 4-substituted imidazolethiones and imidazolones as agonists of .alpha.2B and .alpha.2C adrenergic receptors)
RN 628731-55-5 CAPLUS
CN 1H-Imidazole, 4-[[(2R)-1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl]methyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 628730-35-8 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 628730-36-9 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L6 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:950846 CAPLUS
DOCUMENT NUMBER: 140:13072
TITLE: Novel methods and compositions for alleviating pain
INVENTOR(S): Gil, Daniel W.; Donello, John E.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099289	A2	20031204	WO 2003-US13057	20030423
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003229088	A1	20031211	US 2002-153154	20020521

PRIORITY APPLN. INFO.: US 2002-153154 A 20020521
AB The invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic .alpha.-adrenergic receptor in the absence of .alpha.-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic .alpha.-adrenergic receptor can be, for example, the .alpha.-2B receptor.
IT **423773-40-4 423773-40-4D**, stereoisomers
628730-35-8 628730-36-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.-adrenoceptor activation for alleviating pain)
RN 423773-40-4 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 423773-40-4 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:77587 CAPLUS
DOCUMENT NUMBER: 138:122649
TITLE: Preparation of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors
INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 329,752, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003023098	A1	20030130	US 2001-815362	20010321
US 2002156076	A1	20021024	US 2001-948001	20010906
WO 2002076950	A2	20021003	WO 2002-US8222	20020313
WO 2002076950	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1370533	A2	20031217	EP 2002-723489	20020313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.:
US 1997-985347 B2 19971204
US 1998-205597 B2 19981204
US 1999-329752 B2 19990610
US 2000-679919 A1 20001005
US 2001-815362 A 20010321
WO 2002-US8222 W 20020313
OTHER SOURCE(S): MARPAT 138:122649
GI



I

AB Title compds. I [x = 1-2; R1 = H, halo, alk(en/yn)yl, etc.; R2-3 = H, halo, alk(en/yn)yl, etc.] which are selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors and useful for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated

L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
intraocular pressure with reduced cardiovascular or sedative side effects, are claimed. Also included are methods of making and using such compds. Intrinsic activities towards .alpha.2A, .alpha.2B, .alpha.2C adrenergic receptors of .apprx.100 of the claimed compds. relative to brimonidine/oxymetazoline are tabulated.

IT **157058-47-4P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



IT **157058-44-1P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- **157058-52-1P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- **157058-55-4P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- **226570-89-4P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl}methyl]-, monohydrochloride **226571-02-4P**, 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- **226571-05-7P**, 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- **226571-13-7P**, 1H-Imidazole, 4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- **226571-14-8P**, 1H-Imidazole, 4-[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- **226571-25-1P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- **226571-26-2P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- **226571-35-3P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- **226571-36-4P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride **226571-37-5P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-02-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-13-7 CAPLUS
CN 1H-Imidazole, 4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 226571-14-8 CAPLUS
CN 1H-Imidazole, 4-[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226571-25-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)



IT **226571-57-9P**, 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L6 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-(9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
In I, each x is independently 1 or 2; each R1 is independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H1-2. Each R2 and each R3 are independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H; C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5)o where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or H1-2; or an R2 and an R3 together condense to form a satd., partly satd., or unsatd. ring structure having the formula -[C(R6)p]q-Xs-[C(R6)p]r-Xt-[C(R6)p]u where each R6 is independently H; halogen; C1-4 alkyl; C1-4 alkenyl; C1-4 alkynyl; -COR4 where R4 is H, C1-4 alkyl or C1-4 alkoxy; C3-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl and oxo where each p is independently 1 or 2, q is 0-5, r is 0-5, u is 0-5. Each X is independently O, S, or N and s is 0 or 1; provided that q + r + u + s + t < 6. Y is O; S; N; -[C(R7)z]s-, where each R7 is independently as previously defined for R1, each z is independently 1-2, and s is 1-3; -CH:; -CH:CH-; or Y1CH2, where Y1 is O, N, or S; and the dotted lines in I are optional double bonds, with the proviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsatd., and that if Y is O, N or S, the ring including Y contains at least one said double bond. Intrinsic activities towards .alpha.2A, .alpha.2B, .alpha.2C adrenergic receptors of .apprx.100 of the claimed compds. relative to brimonidine/oxymetazoline are tabulated. Although the methods of prepn. are not claimed, .apprx.100 example prepns. are included.
IT **157058-47-4P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-(9CI) (CA INDEX NAME)



IT **157058-44-1P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- **157058-52-1P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- **157058-55-4P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- **226570-89-4P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride **226571-02-4P**, 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- **226571-05-7P**, 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- **226571-13-7P**, 1H-Imidazole, 4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- **226571-14-8P**, 1H-Imidazole, 4-[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- **226571-25-1P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- **226571-26-2P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- **226571-35-3P**,

L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:754359 CAPLUS
DOCUMENT NUMBER: 137:263032
TITLE: Preparation of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors
INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.; Gomez, Dario G.
PATENT ASSIGNEE(S): Allergan, Inc., USA
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076950	A2	20021003	WO 2002-US8222	20020313
WO 2002076950	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003023098	A1	20030130	US 2001-815362	20010321
EP 1370533	A2	20031217	EP 2002-723489	20020313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-815362 A 20010321
US 1997-985347 B2 19971204
US 1998-205597 B2 19981204
US 1999-329752 B2 19990610
WO 2002-US8222 W 20020313
OTHER SOURCE(S): MARPAT 137:263032
GI



I

AB Compds. (shown as I), which are selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors and useful for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects, are claimed. Also included are methods of making and using such compds.

L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- **226571-36-4P**, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride **226571-37-5P**, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 226571-02-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-13-7 CAPLUS
CN 1H-Imidazole, 4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 226571-14-8 CAPLUS
CN 1H-Imidazole, 4-[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226571-25-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

IT **226571-57-9P**, 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	2002:576071 CAPLUS
DOCUMENT NUMBER:	137:262610
TITLE:	Highly Enantioselective Reformatskii Reaction of Ketones: Chelation-Assisted Enantioface Discrimination
AUTHOR(S):	Ojida, Akio; Yamano, Toru; Taya, Naohiro; Tasaka, Akihiro
CORPORATE SOURCE:	Medicinal Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan
SOURCE:	Organic Letters (2002), 4(18), 3051-3054 CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Highly enantioselective Reformatskii reaction of ketones was accomplished using cinchona alkaloids as chiral ligands. Chelation with the sp2-nitrogen adjacent to the reactive carbonyl center contributed to the enantioface discrimination for the high enantioselectivities.

IT **463304-63-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)
RN 463304-63-4 CAPLUS
CN 2-Oxazolidinone, 3-[(3S)-3-hydroxy-3-(1H-imidazol-4-yl)-3-(2-naphthalenyl)-1-oxopropyl]-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **463304-62-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(chelation-assisted enantioface discrimination in asym. Reformatskii reactions)
RN 463304-62-3 CAPLUS
CN 1,3-Propanediol, 1-(1H-imidazol-4-yl)-1-(2-naphthalenyl)-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:391704 CAPLUS
DOCUMENT NUMBER: 136:401756
TITLE: Preparation of imidazole derivatives for treatment of prostate and breast cancer
INVENTOR(S): Tasaka, Akihiro; Matsunaga, Nobuyuki; Ojida, Akio; Kusaka, Masami
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040470	A1	20020523	WO 2001-JP10079	20011119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002014320	A5	20020527	AU 2002-14320	20011119
JP 2002241377	A2	20020828	JP 2001-353524	20011119
EP 1344777	A1	20030917	EP 2001-982839	20011119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: JP 2000-353634 A 20001120
JP 2000-382056 A 20001215
WO 2001-JP10079 W 20011119
OTHER SOURCE(S): MARPAT 136:401756
GI



I

AB The title compds., e.g. I [R is hydrogen or a protecting group; R1 is lower alkyl or cycloalkyl; and ring A is an optionally substituted 5- or 6-membered ring having an amide linkage], are prepd. I are steroid C17-20 lyase inhibitors and are useful in the treatment of prostate and breast cancer. The process for prepg. I is disclosed. 7-[1-Hydroxy-1-(1H-

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benzo[e]isoindol-3-one inhibited the biosynthesis of testosterone in rats. Formulations are given.

IT **430472-30-3P 430472-32-5P 430472-34-7P**
430472-36-9P 430472-38-1P 430472-39-2P
430472-40-5P 430472-41-6P 430472-42-7P
430472-43-8P 430472-44-9P 430472-45-0P
430472-46-1P 430472-47-2P 430472-48-3P
430472-49-4P 430472-51-8P 430472-53-0P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazole derivs. for treatment of prostate and breast cancer)

RN 430472-30-3 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 430472-38-1 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-32-5 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 430472-39-2 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 2-cyclopropyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-34-7 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 2-ethyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-40-5 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 430472-36-9 CAPLUS



RN 430472-41-6 CAPLUS

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN 3H-Benz[e]isoindol-3-one, 2-(dimethylamino)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-42-7 CAPLUS
CN Benzo[f]phthalazin-4(1H)-one, 2,3-dihydro-8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-43-8 CAPLUS
CN Benzo[f]phthalazin-4(3H)-one, 8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-44-9 CAPLUS
CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 430472-49-4 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 430472-51-8 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 430472-53-0 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 430472-45-0 CAPLUS
CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 430472-46-1 CAPLUS
CN Benzo[g]phthalazin-1(2H)-one, 3,4-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-47-2 CAPLUS
CN Benzo[g]phthalazin-1(2H)-one, 7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-48-3 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:353314 CAPLUS
DOCUMENT NUMBER: 136:365878
TITLE: Methods and compositions for treatment of ocular neovascularization and neural injury
INVENTOR(S): Burke, James A.; Lin, Ton; Wheeler, Larry A.; De Vries, Gerald W.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036162	A2	20020510	WO 2001-US46014	20011101
WO 2002036162	A3	20030821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002030567	A5	20020515	AU 2002-30567	20011101
US 2002094998	A1	20020718	US 2001-998718	20011101
EP 1353692	A2	20031022	EP 2001-990804	20011101
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003082183	A1	20030501	US 2002-20541	20020426

PRIORITY APPLN. INFO.: US 2000-244850P P 20001101
WO 2001-US46014 W 20011101

AB Methods and compns. for the treatment of ocular neovascularization (CNV) and macular degeneration are disclosed. The invention includes combining laser treatment with administration of a neuroprotectant. Seven pigmented rabbits were dosed with either 0.5 mL 0.2% brimonidine or saline administered in 1 eye of each rabbit. One hour later, the animals were treated with a 10-min i.v. infusion of 0.2 mg/kg verteporfin, then the same eye was irradiated 10 min later in the lower fundus with a 689-nm diode laser at 50 J/cm2, 600 mW/cm2 and a spot size of 1.5 mm. Brimonidine reduced the increase in retinal thickness (subretinal cyst + retina) in the lesion produced by PDT.

IT **226571-05-7**, AGN 795 **423773-40-4**, AGN 960
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of ocular neovascularization and neural injury)

RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 423773-40-4 CAPLUS
CN 1(2H)-Naphthalenone, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:848687 CAPLUS
DOCUMENT NUMBER: 136:146981
TITLE: Investigations on inhibitors of human 17.alpha.-hydroxylase-17,20-lyase and their interactions with the enzyme. Molecular modelling of 17.alpha.-hydroxylase-17,20-lyase, part II
AUTHOR(S): Schappach, A.; Holtje, H.-D.
CORPORATE SOURCE: Department of Pharmacy, Institute of Pharmaceutical Chemistry, Heinrich Heine-University, Dusseldorf, Germany
SOURCE: Pharmazie (2001), 56(11), 835-842
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English

AB New methods in treatment of hormone-dependent diseases like prostate or breast cancer have become a major subject in medical and pharmaceutical research. Because of the direct correlation of cancer growth and hormone concn., inhibition of hormone biosynthesis presents a promising strategy in cancer therapy. The key enzyme in androgen biosynthesis is the 17.alpha.-hydroxylase-17,20-lyase a cytochrome P 450 system, which specifically converts gestagens to androgens. Because the 3D-structure of the enzyme is still unknown most recently a ligand-based design was used to gain deeper insights into protein structure and function. In this paper we present mol. modeling studies on compds. acting as competitive inhibitors of the human 17.alpha.-hydroxylase-17,20-lyase. The compds. developed by Hartmann et al. belong to two different structural classes and show a wide range of inhibitory potency. The physico-chem. properties of the mols. were investigated and compared by studying structural flexibility and by calcg. mol. interactions fields. The superimposition of all inhibitors in a low energy conformation yielded in the common pharmacophore. In the second part of the paper individual inhibitors were docked into the active site of the enzyme model of CYP17 developed in our group. The dynamic behavior and stability of the protein-inhibitor-complexes was studied. The protein ligand interactions obsd. in course of the mol. dynamics simulations correspond well with the exptl. data.

IT **157058-47-4**
RL: PRP (Properties)
(mol. modeling of human 17.alpha.-hydroxylase-17,20-lyase with steroidal and non-steroidal inhibitors)

RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:319877 CAPLUS
DOCUMENT NUMBER: 134:340525
TITLE: Process for producing optically active naphthalene derivative and optical resolver therefor
INVENTOR(S): Aoki, Isao; Adachi, Mari; Kawada, Mitsuru; Yamano, Toru; Taya, Naohiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030763	A1	20010503	WO 2000-JP7282	20001019
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000079499	A5	20010508	AU 2000-79499	20001019
EP 1227085	A1	20020731	EP 2000-969902	20001019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001187785	A2	20010710	JP 2000-320499	20001020

PRIORITY APPLN. INFO.: JP 1999-301570 A 19991022
JP 1999-301576 A 19991022
WO 2000-JP7282 W 20001019

OTHER SOURCE(S): MARPAT 134:340525
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for producing an optically active isomer of a compd. represented by formula (I) which comprises: reacting a mixt. of naphthalene derivs. represented by formula I (wherein R represents a nitrogenous heterocyclic group; R1 represents hydrogen, a hydrocarbon group, or a mononuclear arom. heterocyclic group; R2 represents hydrogen or lower alkyl; symbol indicates the position of an asym. carbon atom; and R3 to R8 each represents hydrogen, a hydrocarbon group, hydroxy, etc., provided that R7 may be bonded to R6 or R8 to form a ring contg. an oxygen atom) with an optically active isomer of a 2-hydroxy-4-phenyl-1,3,2-dioxaphosphorinan-2-one or arom. ring-fused 2-hydroxy-1,3,2-dioxaphosphepan-2-one compd. represented by formula (II) or (III), resp. (wherein ring A represents a benzene ring; R10 and R11 each represents hydrogen, a hydrocarbon group, etc. or R10 and R11 in combination represent alkylene; symbol indicates the position of an asym. carbon atom; and rings B and C each represents an arom. ring) to yield salts; sepg. the salts; and then isolating the target isomer. The optically active isomer produced has a steroid C17,20 lyase inhibitory activity and is useful as a preventive/remedy for tumors such as prostatism and mammary cancer. Also provided is a novel optical resolver II or III. Thus, 1.0 g (RS)-1-(6,7-dimethoxynaphthalen-2-yl)-1-

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

(1H-imidazol-4-yl)-2-methyl-1-propanol (IV) (prepn. given) and 822 mg (-)-8-hydroxy-7,9-dioxa-6-phenyl-8-phopshaspiro[4.5]decan-8-one (V) were dissolved in 21 mL ethanol with heating, stirred at room temp. for 6 h, and filtered to give 670 mg (-)-IV.V salt (99% de) in 74% yield which (665 mg) was added to 150 mg 25% aq. NH3, 30 mL H2O, and 20 mL AcOEt, and stirred at room temp. for 30 min. The org. layer was sepd. and concd. in vacuo to give 368 mg (-)-IV (99% de) in 74% yield.

IT **336102-55-7P 336102-62-6P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinanone resolving agents)

RN 336102-55-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 336102-62-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT **336102-65-9 336102-70-6 336102-73-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinanone resolving agents)

RN 336102-65-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 336102-70-6 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 336102-73-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **247173-05-3P 247173-20-2P 247173-40-6P**
247173-41-7P 247173-54-2P 247173-72-4P
247174-12-5P 336102-57-9P 336102-59-1P
336102-61-5P 336102-63-7P 336102-64-8P
336102-66-0P 336102-67-1P 336102-69-3P
336102-71-7P 336102-72-8P 336102-74-0P
336102-75-1P 336102-76-2P 337534-07-3P
337534-08-4P 337534-10-8P 337534-11-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinanone resolving agents)

RN 247173-05-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-20-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-41-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-54-2 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-72-4 CAPLUS
CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247174-12-5 CAPLUS
CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 336102-57-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)-, compd. with (-)-8-hydroxy-6-phenyl-7,9-dioxa-8-phosphaspiro[4.5]decane 8-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-56-8
CMF C13 H17 O4 P

Rotation (-).



CM 2

CRN 336102-55-7
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



RN 336102-59-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-58-0
CMF C19 H22 N2 O2

Rotation (-).



CM 2

CRN 98674-91-0
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (-).



RN 336102-61-5 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (+)-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-60-4
CMF C19 H21 N3 O2

Rotation (+).

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 98674-82-9
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (+).



RN 336102-63-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (-)-4-(4-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-62-6
CMF C18 H20 N2 O2

Rotation (-).



CM 2

CRN 98674-89-6
CMF C11 H14 Cl O4 P

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Rotation (-).



RN 336102-64-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-62-6
CMF C18 H20 N2 O2

Rotation (-).



CM 2

CRN 98674-83-0
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (-).



RN 336102-66-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CRN 336102-65-9
CMF C20 H22 N2 O3



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).



RN 336102-67-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-65-9
CMF C20 H22 N2 O3



CM 2

CRN 98674-90-9
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (+).

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 336102-69-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-68-2
CMF C19 H20 N2 O3



CM 2

CRN 98674-86-3
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).



RN 336102-71-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 2

CRN 98674-91-0
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (-).



RN 336102-74-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-73-9
CMF C18 H19 N3 O2



CM 2

CRN 98674-90-9
CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (+).



RN 336102-75-1 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 1

CRN 336102-70-6
CMF C20 H23 N3 O2



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).



RN 336102-72-8 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (-)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-70-6
CMF C20 H23 N3 O2



L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-73-9
CMF C18 H19 N3 O2



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).



RN 336102-76-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-73-9
CMF C18 H19 N3 O2



CM 2

CRN 98674-82-9

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (+).



RN 337534-07-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (11bR)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P



L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 98674-86-3
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).

RN 337534-11-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-62-6
CMF C18 H20 N2 O2

Rotation (-).

CM 2

CRN 98674-86-3
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 337534-08-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 98674-80-7
CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).



RN 337534-10-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 337534-09-5
CMF C18 H20 N2 O2

Rotation (-).

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **336103-01-6P 336103-02-7P 336103-04-9P**
336103-06-1P 337534-12-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(process for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinanone resolving agents)
RN 336103-01-6 CAPLUS
CN Cyclohexanecarboxylic acid, 2-(aminocarbonyl)-, (1S,2R)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-00-5
CMF C8 H13 N O3

Absolute stereochemistry.

CM 2

CRN 247173-41-7
CMF C19 H22 N2 O3

RN 336103-02-7 CAPLUS
CN Benzeneacetic acid, .alpha.-hydroxy-, (.alpha.S)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-41-7
CMF C19 H22 N2 O3

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 17199-29-0
CMF C8 H8 O3

Absolute stereochemistry. Rotation (+).



RN 336103-04-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8
CMF C18 H19 N3 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 336103-06-1 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-05-0
CMF C20 H23 N3 O2

Absolute stereochemistry.



CM 2

CRN 98674-87-4
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).



RN 337534-12-0 CAPLUS
CN Sulfamic acid, [(1S)-1-phenylethyl]-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

L6 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 1

CRN 247173-41-7
CMF C19 H22 N2 O3



CM 2

CRN 50573-41-6
CMF C8 H11 N O3 S

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:319876 CAPLUS
DOCUMENT NUMBER: 134:340505
TITLE: Preparation of imidazol-4-ylmethanols as steroid C17-20 lyase inhibitors
INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030762	A1	20010503	WO 2000-JP7283	20001019
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000079500	A5	20010508	AU 2000-79500	20001019
EP 1222174	A1	20020717	EP 2000-969903	20001019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2002080458	A2	20020319	JP 2000-327022	20001020
US 6649643	B1	20031118	US 2002-110599	20020412

PRIORITY APPLN. INFO.: JP 1999-301556 A 19991022
JP 2000-189728 A 20000620
WO 2000-JP7283 W 20001019

OTHER SOURCE(S): MARPAT 134:340505
GI



I

II

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

AB Title compds. (I) {wherein R = H or a protecting group; R1 = (cyclo)alkyl; R3 and R5 = H, acyl, halo, or (un)substituted alkyl, hydroxyl, thio, or amino; R4 = (un)substituted aryl, heterocyclic, or carbamoyl; or R3 and R4 form a 5- or 6-membered O-contg. ring; or R4 and R5 form a 5- or 6-membered O-contg. ring; R6 = (halo)alkyl; n = 0-3; or salt thereof}, which have an inhibitory activity on steroid C17-20 lyase, were prepd. For example, Me 6-(1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl)-2-naphthoate (prepn. given) was deesterified using NaOH and MeOH in THF, converted to the amide using MeNH2, and deprotected using pyridinium chloride to give the imidazolyl naphthalenemethanol II. II inhibited steroid C17-20 lyase with IC50 of 6.1 nM and showed inhibitory activity on testosterone biosynthesis (testosterone concn. of groups of rats receiving test compds. to control groups) of 4.5%. I are useful for the prevention and treatment of breast cancer or prostate cancer (no data).

IT **247173-41-7P**, 1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **247173-54-2P**, N-[6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl]acetamide
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 247173-41-7 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-54-2 CAPLUS

CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **336103-03-8P**, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide **337520-97-5P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthonitrile **337521-57-0P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl-1-naphthamide **337521-60-5P**, 2-Hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide **337521-62-7P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-1-naphthamide **337521-63-8P** **337521-94-5P**, (1H-Imidazol-4-yl)(naphtho[2,1-b]furan-7-yl)ketone **337521-99-0P**, (1H-Imidazol-4-yl)[naphtho[2,3-d][1,3]dioxol-6-yl]ketone

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-62-7 CAPLUS

CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-63-8 CAPLUS

CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-[(methylamino)carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-94-5 CAPLUS

CN Methanone, 1H-imidazol-4-ylnaphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

337522-08-4P, (2,3-Dihydro-1H-benzo[f]chromen-8-yl)(1H-imidazol-4-yl)ketone **337522-19-7P**, (1,2-Dihydronaphtho[2,1-b]furan-7-yl)(1H-imidazol-4-yl)ketone **337522-26-6P**, (2,3-Dihydronaphtho[2,3-b]furan-6-yl)(1H-imidazol-4-yl)methanol **337522-27-7P**, (2,3-Dihydronaphtho[2,3-b]furan-6-yl)(1H-imidazol-4-yl)ketone **337522-28-8P**, 1-(2,3-Dihydronaphtho[2,3-b]furan-6-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **337534-08-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 336103-03-8 CAPLUS

CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 337520-97-5 CAPLUS

CN 2-Naphthalenecarbonitrile, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

RN 337521-57-0 CAPLUS

CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-60-5 CAPLUS

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337521-99-0 CAPLUS

CN Methanone, 1H-imidazol-4-ylnaphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)



RN 337522-08-4 CAPLUS

CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 337522-19-7 CAPLUS

CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 337522-26-6 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-27-7 CAPLUS
CN Methanone, (2,3-dihydronaphtho[2,3-b]furan-6-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 337522-28-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-b]furan-6-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337534-08-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CRN 98674-80-7
CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).



IT **337521-96-7P**, 1-(1H-Imidazol-4-yl)-1-[naphtho[2,3-d][1,3]dioxol-6-yl]-2-methyl-1-propanol **337522-45-9P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl-2-naphthamide **337522-94-8P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl-2-naphthamide **337523-27-0P**, Ethyl {{6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoyl]amino}acetate **337523-39-4P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl-2-naphthamide **337523-51-0P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl-2-naphthamide **337523-67-8P**, 1-[5-Chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 337521-96-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-naphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)



RN 337522-45-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 337522-94-8 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)



RN 337523-27-0 CAPLUS
CN Glycine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 337523-39-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-51-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-67-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT **336102-55-7P**, (S)-(-)-1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **336102-68-2P**, Methyl 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoate **336102-70-6P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-2-naphthamide **336102-73-9P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide **337521-66-1P**, 1-(1H-Imidazol-4-yl)-2-methyl-1-(6-phenyl-2-naphthyl)-1-propanol **337521-68-3P**, 1-[6-(2-Furyl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **337521-70-7P**, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(2-thienyl)-2-naphthyl]-1-propanol **337521-74-1P**, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-propanol **337521-77-4P**, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3,4-tetrazol-5-yl)-2-naphthyl]-1-propanol **337521-79-6P**, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1H-pyrazol-4-yl)-2-naphthyl]-1-propanol **337521-81-0P**, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-propanol **337521-84-3P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide **337521-86-5P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy-2-naphthamide **337521-89-8P**, 1-(1H-Imidazol-4-yl)-1-(naphtho[2,1-b]furan-7-yl)-2-methyl-1-propanol **337521-95-6P**, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **337522-00-6P**, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **337522-09-5P**, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)ethanol **337522-10-8P**, 1-(2,3-Dihydro-1H-benzo[f]chromen-8-yl)-1-(1H-imidazol-4-yl)propanol **337522-12-0P**, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-ethanol **337522-21-1P**, 1-(1,2-Dihydronaphtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-propanol **337522-31-3P** **337522-33-5P**, (-)-N-{6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl}acetamide **337522-40-4P** **337522-41-5P**, N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-49-3P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropyl-2-naphthamide **337522-53-9P**, N-Butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-57-3P**, N-Cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-61-9P**, N-Cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-64-2P**, N-Cyclopropylmethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-67-5P**, N-Cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-69-7P**, N-Cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-72-2P**, N-Cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-74-4P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-77-7P**, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337522-79-9P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl-2-naphthamide **337522-83-5P**, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide **337522-88-0P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
methylpropyl}-N,1-dimethyl-2-naphthamide **337522-99-3P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl}-3-methyl-2-naphthamide **337523-03-2P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl-2-naphthamide **337523-06-5P**, 1-(1H-Imidazol-4-yl)-2-methyl-1-[6-(1-pyrrolidinylcarbonyl)-2-naphthyl]-1-propanol **337523-11-2P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1,3-thiazol-2-yl)-2-naphthamide **337523-16-7P**, N-Ethoxy-6-[1-hydroxy-1-(1H-imidazol-4-yl}-2-methylpropyl]-2-naphthamide **337523-20-3P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropoxy-2-naphthamide **337523-24-7P**, N-(2-Hydroxyethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337523-32-7P 337523-36-1P 337523-47-4P 337523-61-2P**, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl}-2-methylpropyl]-N-methyl-2-naphthamide **337523-63-4P**, (S)-(-)-N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337523-65-6P**, (S)-(-)-N-Cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide **337523-76-9P**, 1-[5-Chloro-6-(1,3-oxazol-5-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **337523-82-7P**, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-naphthamide **337523-86-1P**, 1-(1H-Imidazol-4-yl)-3-methyl-1-[6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-butanol **337523-94-1P**, 1-(1H-Imidazol-4-yl)-3-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl}-1-butanol **337524-00-2P**, 1-[6-(4,4-Dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol **337524-05-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 336102-55-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 336102-68-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337521-70-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(2-thienyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-74-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-77-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-tetrazol-5-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-79-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1H-pyrazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 336102-70-6 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 336102-73-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-66-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-phenyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 337521-68-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(2-furanyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 337521-81-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337521-84-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-86-5 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy- (9CI) (CA INDEX NAME)



RN 337521-89-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-naphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)



RN 337521-95-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-00-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337522-09-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 337522-10-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-ethyl- (9CI) (CA INDEX NAME)



RN 337522-12-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-21-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-.alpha.-ethyl- (9CI) (CA INDEX NAME)



RN 337522-31-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 337522-33-5 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 337522-40-4 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 337522-33-5
CMF C19 H21 N3 O2

Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 337522-41-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-49-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337522-53-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-butyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-57-3 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-61-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-64-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(cyclopropylmethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-67-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-69-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-72-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-74-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-77-7 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337522-79-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 337522-83-5 CAPLUS
CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337522-88-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl- (9CI) (CA INDEX NAME)



RN 337522-99-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 337523-03-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 337523-06-5 CAPLUS
CN Pyrrolidine, 1-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337523-11-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 337523-16-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethoxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337523-20-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 337523-24-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(2-hydroxyethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337523-32-7 CAPLUS
CN L-Alanine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 337523-36-1 CAPLUS
CN D-Alanine, N-[[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 337523-47-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-(cyclopropylhydroxy-1H-imidazol-4-ylmethyl)-N-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337523-61-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 337523-63-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethyl-6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 337523-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337523-76-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-(5-oxazolyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337523-82-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]- (9CI) (CA INDEX NAME)



RN 337523-86-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-[6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 337523-94-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-[6-(5-oxazolyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 337524-00-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337524-05-7 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8
CMF C18 H19 N3 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:12424 CAPLUS
DOCUMENT NUMBER: 134:86245
TITLE: Preparation of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors.
INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 145 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000586	A1	20010104	WO 2000-US15795	20000608
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1104407	A1	20010606	EP 2000-939699	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002156076	A1	20021024	US 2001-948001	20010906

PRIORITY APPLN. INFO.: US 1999-329752 A 19990610
US 1997-985347 B2 19971204
US 1998-205597 B2 19981204
WO 2000-US15795 W 20000608
US 2000-679919 A1 20001005
OTHER SOURCE(S): MARPAT 134:86245
GI



I

AB Title compds. {I; dotted lines = optional double bonds; R = H, alkyl; X = S, CHR1; R1 = H, alkyl, null; Y = O, N, S, [C(R1)n]y, CH:CH, YlCH2; y = 1-3; n = 1, 2; R2 = H, alkyl, halo, OH, alkoxy, alkenyl, acyl, alkynyl, etc.; R3, R4 = H, alkyl, halo, alkenyl, acyl, alkynyl, etc.; R3R4 = atoms to form (unsatd.) (heterocyclic) ring], were prepd. Thus, 1-(dimethylsulfamoyl)imidazole in THF at -78.degree. was treated with BuLi and tert-butyldimethylsilyl chloride followed by warming to room temp., stirring overnight, cooled to -20.degree., and treatment with BuLi and 3-thiophenecarboxaldehyde followed by warming to room temp. and stirring overnight to give 2-(tert-butyldimethylsilyl)-5-(hydroxythiophen-2-ylmethyl)imidazole-1-sulfonic acid dimethylamide. This was treated sequentially with Bu4NF, Et3SiH/CF3CO2H/CH2Cl2, and aq. HCl to give 4(5)-thiophen-3-ylmethyl-1H-imidazole. Tested I as eyedrops at 0.03-1% reduced intraocular pressure in cynomolgus monkeys by 12.4-33% and showed no sedative activity.

IT **157058-47-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



IT **157058-55-4P 226570-89-4P 226571-02-4P**
226571-05-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-02-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



IT **157058-44-1 157058-52-1 226571-13-7**
226571-14-8 226571-25-1 226571-26-2
226571-35-3 226571-36-4 226571-37-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)
RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-13-7 CAPLUS
CN 1H-Imidazole, 4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 226571-14-8 CAPLUS
CN 1H-Imidazole, 4-[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 226571-25-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 226571-35-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)





RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)

IT **226571-57-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

L6 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:911226 CAPLUS
DOCUMENT NUMBER: 134:56671
TITLE: Process for the preparation of 4-alkanoylimidazole derivatives and 1-(2-naphthyl)-1-(1H-imidazol-4-yl)alkanol derivatives
INVENTOR(S): Kawakami, Jun-ichi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078727	A1	20001228	WO 2000-JP4036	20000621
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001064264	A2	20010313	JP 2000-191081	20000621
EP 1193258	A1	20020403	EP 2000-940770	20000621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1999-175070 A 19990622
WO 2000-JP4036 W 20000621
OTHER SOURCE(S): CASREACT 134:56671; MARPAT 134:56671
GI



AB An industrially advantageous process for the prepn. of compds. of general formula (I; wherein the ring A is an optionally substituted imidazole ring; R is an optionally substituted hydrocarbon group or a heterocyclic

L6 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
group; and R1, R2, R3, R4, R5, R6, and R7 are each hydrogen, optionally substituted hydrocarbyl, OH, SH, NH2, acyl, halogeno, or the like) comprises addn. reaction of 4-cyanoimidazole (II; the ring A is same as above) with R-M1 (R is same as above; M1 = alkali metal, Mg-Y1; Y1 = halo) to give 4-acylimidazole (III; R and ring A are same as above), followed by addn. reaction of III with naphthalene alkali metals (IV; R1 - R7 are = same as above; M2 is alkali metal, Mg-Y2; Y2 is halo). This process is reduced in the no. of steps, attains a high yield, and dispenses with the use of a heavy metal compd. The compds. I exhibit a steroid C17-C20 lyase inhibitory activity (no data). Thus, a soln. of 42.7 g 4-cyanoimidazole in 500 mL THF was added dropwise to a 1.1. M soln. of isopropylmagnesium bromide in THF (1.4 L) over a period of 30 min, stirred at 15-25.degree., treated dropwise with 10% aq. H2SO4, stirred for 30 min, neutralized to pH 8 with 30 aq. NaOH, and extd. with EtOAc (300 L .times. 2) to give 82% 1-(1H-imidazol-4-yl)-2-methyl-1-propanone (V). 2-Bromo-6-methoxynaphthalene (5.15 g) was added dropwise to a mixt. of 0.55 g and 3 mg iodine in THF at 50.degree. and stirred at 15-25.degree. for 1.5 h, followed by adding dropwise a soln. of 1 g V in THF, and the resulting mixt. was stirred at 15-25.degree. for 8 h to give, after workup, 84% 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropanol.

IT **247173-05-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-alkanoylimidazole derivs. and .alpha.-(2-naphthyl)-.alpha.-(1H-imidazolyl)alkanol derivs. by addn. reaction of cyanoimidazoles with alkylmagnesium bromides followed by naphthylmagnesium bromide)
RN 247173-05-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:691084 CAPLUS
DOCUMENT NUMBER: 131:299449
TITLE: Preparation of azolylmethylnaphthalenes and related compounds as steroid C17,20-lyase inhibitors.
INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaoka, Masuo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9954309	A1	19991028	WO 1999-JP2143	19990422
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2328973	AA	19991028	CA 1999-2328973	19990422
AU 9935346	A1	19991108	AU 1999-35346	19990422
JP 2000007658	A2	20000111	JP 1999-114398	19990422
EP 1073640	A1	20010207	EP 1999-917102	19990422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6573289	B1	20030603	US 2000-673591	20001018
US 2003236274	A1	20031225	US 2003-443379	20030522

PRIORITY APPLN. INFO.: JP 1998-113801 A 19980423
WO 1999-JP2143 W 19990422
US 2000-673591 A3 20001018
OTHER SOURCE(S): MARPAT 131:299449
GI



I

AB Title compds. [I; A1 = (substituted) imidazolyl, thiazolyl, oxazolyl, pyridyl; R11 = H, (substituted) hydrocarbyl, monocyclic heteroaryl; R21 = H, (substituted) alkyl; R3-R9 = H, (substituted) hydrocarbyl, OH, SH, amino, acyl, halo; R21 = (substituted) alkyl], and salts or prodrugs thereof, were prepd. Thus, 2-bromo-6-methoxynaphthalene in THF at -78.degree. was treated with BuLi and then with 4-formyl-1-trityl-1H-imidazole to give (6-methoxynaphthalen-2-yl)(1-trityl-1H-imidazol-4-yl)methanol. The product was refluxed with MnO2 in CHCl3 to give the ketone, which was detritylated with HCO2H in THF to give (1H-imidazol-4-yl)(6-methoxynaphthalen-2-yl) ketone. The latter in THF at -10.degree. was treated with Me2CHMgBr in THF to give 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methyl-1-propanol. This inhibited rat steroid C17,20-lyase with IC50 = 33 nM. I drug formulations are given.

IT **247173-05-3P 247173-06-4P 247173-07-5P**
247173-09-7P 247173-11-1P 247173-12-2P
247173-13-3P 247173-14-4P 247173-17-7P
247173-18-8P 247173-19-9P 247173-20-2P
247173-21-3P 247173-22-4P 247173-24-6P
247173-25-7P 247173-26-8P 247173-27-9P
247173-28-0P 247173-29-1P 247173-30-4P
247173-31-5P 247173-32-6P 247173-33-7P
247173-34-8P 247173-35-9P 247173-36-0P
247173-37-1P 247173-38-2P 247173-39-3P
247173-40-6P 247173-41-7P 247173-42-8P
247173-43-9P 247173-44-0P 247173-45-1P
247173-46-2P 247173-47-3P 247173-48-4P
247173-49-5P 247173-50-8P 247173-51-9P
247173-52-0P 247173-53-1P 247173-54-2P
247173-55-3P 247173-56-4P 247173-57-5P
247173-58-6P 247173-59-7P 247173-60-0P
247173-61-1P 247173-62-2P 247173-63-3P
247173-64-4P 247173-65-5P 247173-66-6P
247173-68-8P 247173-69-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azolylmethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)

RN 247173-05-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-06-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-methyl- (9CI) (CA INDEX NAME)



RN 247173-07-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 247173-09-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-cyclopropyl-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-08-6
CMF C18 H18 N2 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 247173-11-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1,1-dimethylethyl)-.alpha.-(6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-10-0
CMF C19 H22 N2 O2



L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 247173-12-2 CAPLUS
CN 3-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-13-3 CAPLUS
CN 4-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-14-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)



RN 247173-17-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-fluoro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-18-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-ethyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-19-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 247173-20-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)



RN 247173-21-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-cyclopentyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-27-9 CAPLUS
CN 1H-Imidazole, 4-[(6-methoxy-2-naphthalenyl)(1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 247173-28-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethenyl)- (9CI) (CA INDEX NAME)



RN 247173-29-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-30-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[5-[1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-6-methoxy-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-22-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-24-6 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 247173-25-7 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 247173-26-8 CAPLUS
CN 1H-Imidazole, 4-[methoxy(6-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-31-5 CAPLUS
CN 1,6-Naphthalenedimethanol, .alpha.6-1H-imidazol-4-yl-2-methoxy-.alpha.1-methyl-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-32-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-33-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(1-methylethenyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-34-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(1-methylethyl)-2-

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-35-9 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, [[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]oxy]methyl ester (9CI) (CA INDEX NAME)



RN 247173-36-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(1-methylethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-37-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-38-2 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-39-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(2-methoxyethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-41-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-42-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-43-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5,6-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-44-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-7-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-45-1 CAPLUS
CN 1,6-Naphthalenedimethanol, .alpha.6-1H-imidazol-4-yl-2-methoxy-.alpha.6-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-46-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(methoxymethyl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-47-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-48-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethenyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-49-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-bromo-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-50-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(fluoromethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-51-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5,7-dimethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-52-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-53-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-54-2 CAPLUS
CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-59-7 CAPLUS
CN Ethanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-60-0 CAPLUS
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-61-1 CAPLUS
CN 1-Propanone, 1-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 247173-62-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-55-3 CAPLUS
CN Urea, N'-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 247173-56-4 CAPLUS
CN Urea, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 247173-57-5 CAPLUS
CN Methanesulfonamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-58-6 CAPLUS
CN 2,6-Naphthalenedimethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 247173-63-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-methyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-64-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethynyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-65-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(methylthio)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-66-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-1-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-68-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-69-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-[6-(1-methylethyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



IT **247174-67-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azolylmethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)
RN 247174-67-0 CAPLUS
CN Methanone, (5-fluoro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



IT **247173-72-4P 247173-89-3P 247173-95-1P 247174-00-1P 247174-01-2P 247174-05-6P 247174-12-5P 247174-17-0P 247174-24-9P 247174-25-0P 247174-26-1P 247174-35-2P 247174-36-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azolylmethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)
RN 247173-72-4 CAPLUS
CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247173-89-3 CAPLUS
CN Methanone, 1H-imidazol-4-yl-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 247173-95-1 CAPLUS
CN Methanone, (5-chloro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 247174-00-1 CAPLUS
CN Methanone, [5-[1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-6-methoxy-2-naphthalenyl]-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 247174-01-2 CAPLUS
CN Methanone, 1H-imidazol-4-yl[6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 247174-05-6 CAPLUS
CN Methanone, 1H-imidazol-4-yl[6-methoxy-5-(1-methylethenyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247174-12-5 CAPLUS
CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 247174-17-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247174-24-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 247174-25-0 CAPLUS
CN Methanone, 1H-imidazol-4-yl[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247174-26-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247174-35-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5,7-dimethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247174-36-3 CAPLUS
CN Methanone, 1H-imidazol-4-yl(6-methoxy-5,7-dimethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:375530 CAPLUS
DOCUMENT NUMBER: 131:19013
TITLE: Preparation of .alpha.2B and .alpha.2C adrenoceptor agonists
INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928300	A1	19990610	WO 1998-US25669	19981203
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2312334	AA	19990610	CA 1998-2312334	19981203
AU 9918025	A1	19990616	AU 1999-18025	19981203
AU 744798	B2	20020307		
EP 1036065	A1	20000920	EP 1998-962883	19981203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9813381	A	20001003	BR 1998-13381	19981203
JP 2001524542	T2	20011204	JP 2000-523194	19981203
NZ 504667	A	20030328	NZ 1998-504667	19981203
NO 2000002773	A	20000802	NO 2000-2773	20000530
US 2002156076	A1	20021024	US 2001-948001	20010906

PRIORITY APPLN. INFO.: US 1997-985347 A 19971204
WO 1998-US25669 W 19981203
US 1998-205597 B2 19981204
US 1999-329752 B3 19990610
US 2000-679919 A1 20001005

OTHER SOURCE(S): MARPAT 131:19013

AB Title compds. of diverse structural type were prepd. Thus, 7-methoxy-1-tetralone was condensed with 1-dimethylsulfamoyl-2-tert-butyldimethylsilyl-5-imidazolecarboxaldehyde (prepn. given) and the product converted in 3 steps to 4(S)-(7-methoxy-1,2,3,4-tetrahydronaphth-2-ylmethyl)-1H-imidazole. Data for biol. activity of title compds. were given.

IT **157058-44-1P 157058-47-4P 157058-52-1P 157058-55-4P 226570-89-4P 226571-02-4P 226571-05-7P 226571-13-7P 226571-14-8P 226571-25-1P 226571-26-2P 226571-35-3P 226571-36-4P 226571-37-5P 226571-43-3P 226571-55-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)

RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226570-89-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-02-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-13-7 CAPLUS
CN 1H-Imidazole, 4-[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 226571-14-8 CAPLUS
CN 1H-Imidazole, 4-[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 226571-25-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-(9CI) (CA INDEX NAME)



RN 226571-43-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 226571-55-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]-, (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 226571-05-7
CMF C14 H20 N2



L6 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

IT **226571-57-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of .alpha.2B and .alpha.2C adrenoceptor agonists)
RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:244636 CAPLUS
DOCUMENT NUMBER: 130:252360
TITLE: Preparation of dihydronaphthalene compounds
INVENTOR(S): Hartmann, Rolf Wolfgang; Wachall, Bertil; Yoshihama, Makoto; Nakakoshi, Masamichi; Nomoto, Shin; Ikeda, Yoshikazu
PATENT ASSIGNEE(S): Yukijirushi Nyugyo Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918075	A1	19990415	WO 1998-JP4426	19981001
W: AU, CA, CN, FI, HU, IL, JP, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9808954	A	19990412	ZA 1998-8954	19981001
AU 9892810	A1	19990427	AU 1998-92810	19981001
AU 743405	B2	20020124		
EP 1028110	A1	20000816	EP 1998-945556	19981001
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
NZ 501822	A	20011221	NZ 1998-501822	19981001
RU 2203890	C2	20030510	RU 1999-127323	19981001
CN 1117732	B	20030813	CN 1998-808436	19981001
FI 2000000207	A	20000201	FI 2000-207	20000201
NO 2000001289	A	20000310	NO 2000-1289	20000310
US 2002032211	A1	20020314	US 2001-866179	20010525
US 6559157	B2	20030506		

PRIORITY APPLN. INFO.: JP 1997-284263 A 19971002
WO 1998-JP4426 W 19981001
US 1999-424126 B1 19991117

OTHER SOURCE(S): MARPAT 130:252360
GI



I

AB Dihydronaphthalene compds. I (R1 = H, OH, alkyloxy; R2 = alkyl, aralkyl, Ph; R3 = alkyl, Ph, pyridyl, imidazolyl), useful as 17.alpha.-hydroxylase/C17-20-lyase inhibitors, thromboxane A2 synthesis inhibitors, and aromatase inhibitors, were prepd. I (R1 = H, R2 = Me, R3 = 3-pyridyl) showed 17.alpha.-hydroxylase/C17-20-lyase and aromatase inhibitor activity..

IT **157058-45-2P 157058-46-3P 157058-47-4P**
221651-52-1P 221651-54-3P 221651-56-5P
221651-61-2P 221651-64-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of dihydronaphthalenes)

L6 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 157058-45-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy-(9CI) (CA INDEX NAME)



RN 157058-46-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy-(9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-(9CI) (CA INDEX NAME)



RN 221651-52-1 CAPLUS
CN 1(2H)-Naphthalenone, 5-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)



RN 221651-54-3 CAPLUS
CN 1(2H)-Naphthalenone, 6-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-(9CI) (CA INDEX NAME)

L6 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 221651-56-5 CAPLUS
CN 1(2H)-Naphthalenone, 7-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 221651-61-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-propoxy- (9CI) (CA INDEX NAME)



RN 221651-64-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-(2-methylpropoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:358249 CAPLUS
DOCUMENT NUMBER: 125:75343
TITLE: Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17 and P450 TxA2
AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber, Dorothea; Waechter, Gerald A.; Gruen, Gertrud L.; Sergejew, Tom F.
CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ. Saarlandes, Saarbruecken, D-66041, Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 329(5), 251-261
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: VCH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing of OCH3 substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-spacer between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 arom (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 TxA2 (citrated human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 scc (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compds. were examd. in Sprague Dawley rats regarding P 450 TxA2 inhibition, redn. of plasma testosterone concn., antiuterotropic activity (inhibition of the uterotropic activity of androstenedione), redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent new azole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 arom and/or P 450 17 were found; 7-OCH3-2-(imidazol-4-ylmethylene)-1-tetralone (I) and 7-OCH3-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 arom in vitro know so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH3 deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 TxA2, whereas 7-OCH3-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH3-2-imidazol-1-yl-3,4-dihydronaphthalene addnl. show strong inhibition of P 450 arom and P 450 17. Structure-activity relations are discussed. Regarding the other steroidogenic P 450 enzymes as well as corticosterone formation, the compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concns. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 arom fadrozole. The compds. show activity in the aforementioned in vivo tests.

IT **157058-44-1P 157058-45-2P 157058-46-3P 157058-47-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotropic activity and mammary tumor inhibition)

RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 157058-45-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 157058-46-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



IT **157058-52-1P 157058-53-2P 157058-55-4P 178880-06-3P**

L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotropic activity and mammary tumor inhibition)

RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 178880-06-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 157058-54-3
CMF C15 H18 N2 O

L6 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4



L6 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:97011 CAPLUS
DOCUMENT NUMBER: 124:260928
TITLE: Novel nonprostanoid prostacyclin (PGI2) mimetics with heterocyclic moiety
AUTHOR(S): Nagao, Yuuki; Takahashi, Kanji; Torisu, Kazuhiko; Kondo, Kigen; Hamanaka, Nobuyuki
CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
SOURCE: Heterocycles (1996), 42(2), 517-23
CODEN: HTCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Structural modification of [[6-[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(2-benzhydryloxyiminopentyl)-1,2,3,4-tetrahydro-5-naphthyloxy]acetic acid], previously identified as a PGI2 agonist without a PG skeleton, was examd. Such analogs were for example, [[6-[[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid or [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid. Conversion of the oxime moiety in [[6-[2-[(diphenylmethoxy)imino]pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid to a pyrazole led to [[6-[[4-(diphenylmethyl)-1H-pyrazol-1-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., [2-(4-benzhydrylpylazoyl)methyl-1,2,3,4-tetrahydro-5-naphthyloxy]acetic acid] which strongly inhibited ADP-induced aggregation of human platelets in vitro.
IT **150559-29-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of [[[[(phenylmethoxy)imino]alkyl]naphthalenyl]oxy]acetate analogs as nonprostanoid prostacyclin mimetics)
RN 150559-29-8 CAPLUS
CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:827732 CAPLUS
DOCUMENT NUMBER: 124:202093
TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV. [Erratum to document cited in CA123:198689]
AUTHOR(S): Hamanaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Tokumoto, H.; Kondo, K.
CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(18), 2179
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The errors were not reflected in the abstr. or the index entries.
IT **150559-29-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(PGI2 agonist activity of (Erratum))
RN 150559-29-8 CAPLUS
CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:612212 CAPLUS
DOCUMENT NUMBER: 123:198691
TITLE: Medetomidine analogs as .alpha.-adrenergic agonists
AUTHOR(S): Amemiya, Yoshiya; Hus, Fulian; Shams, Gamal; Feller, Dennis R.; Venkataraman, B. V.; Patil, Popat N.; Miller, Duane D.
CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 403-10
CODEN: EJPSBZ; ISSN: 0301-5068
PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:198691
AB Recently, it has been reported that medetomidine is a new 4-substituted imidazole analog possessing selective and potent .alpha.2-adrenergic properties. It has been shown that it reduces blood pressure, heart rate and saliva secretion. At the present time is sedative and hypotensive effects seem to be manifest in the same dose range. We have initiated a program to see if it is possible to sep. these activities with analogs of medetomidine. The initial studies have been directed at procedures for the conversion of the imidazolines, a common structure of .alpha.-adrenergic drugs, to the corresponding imidazoles. It was found that 2-substituted and 2,4-disubstituted imidazolines can easily be converted into imidazoles using 10% Pd/C in refluxing toluene, while in some instances there are some difficulties with the conversion of 4-substituted imidazolines to the imidazoles. The synthesis of 1- or 2-(2-or 4-imidazolylmethyl)naphthalene analogs of medetomidine are also described.
IT **137967-88-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of 4-substituted imidazoles)
RN 137967-88-5 CAPLUS
CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:612188 CAPLUS
DOCUMENT NUMBER: 123:111932
TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs of .alpha.- and .beta.-naphthalene
AUTHOR(S): Amemiya, Yoshiya; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl
CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 91-112
CODEN: EJPSBZ; ISSN: 0301-5068
PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Seven analogs of medetomidine and naphazoline were synthesized and evaluated for their .alpha.1- (aorta) and .alpha.2- (platelet) activities. The analogs were composed of 2- and 4-substituted imidazoles and imidazolines attached through a methylene bridge to either an .alpha.- or .beta.-naphthalene ring system. In general the .alpha.-naphthlene analogs were found to be the most potent inhibitors of platelet aggregation. .alpha.-Naphthalene analogs were partial agonists while the .beta.-naphthalene analogs were antagonists in .alpha.1-adrenergic system (aorta).

IT **137967-82-9P 166034-65-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and adrenergic activities of medetomidine and naphazoline analogs)

RN 137967-82-9 CAPLUS
CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 166034-65-7 CAPLUS
CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 137967-88-5
CMF C15 H14 N2

L6 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **137967-88-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and adrenergic activities of medetomidine and naphazoline analogs)

RN 137967-88-5 CAPLUS
CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:598392 CAPLUS
DOCUMENT NUMBER: 123:198689
TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV
AUTHOR(S): Hamanaka, Nobuyuki; Takahasi, Kanji; Nagao, Yuuki; Torisu, Kazuhiko; Tokumoto, Hidekado; Kondo, Kigen
CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(10), 1083-6
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The synthesis and biol. evaluation of a novel series of di- or tetrahydronaphthalen-5-oxyacetic acid derivs. with a 4-benzhydrylpyrazolyl group is described. Among these compds., I has been identified as a highly potent PGI2 agonist with an exceptionally long in vivo duration of action.

IT **150559-29-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(PGI2 agonist activity of)

RN 150559-29-8 CAPLUS
CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:513524 CAPLUS
DOCUMENT NUMBER: 122:265379
TITLE: Preparation of (cyanobenzyl)azole derivatives as aromatase inhibitors
INVENTOR(S): Shibata, Tomoyuki; Sugimura, Yukio; Tanzawa, Kazuhiko; Takahashi, Masaaki; Kobayashi, Tomowo; Mitsuhashi, Yoshihiro
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9408973	A1	19940428	WO 1993-JP1509	19931020
W: AU, CA, CZ, FI, HU, KR, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9352855	A1	19940509	AU 1993-52855	19931020
JP 06263742	A2	19940920	JP 1993-261438	19931020

PRIORITY APPLN. INFO.: JP 1992-283177 19921021
WO 1993-JP1509 19931020
OTHER SOURCE(S): MARPAT 122:265379
GI



I



II



III

AB The title compds. (I; R1 = imidazolyl, triazolyl or tetrazolyl each of which may be substituted by Me and/or Et; R2 = naphthyl, phenanthryl or anthryl each of which may be substituted by substituent(s) selected from C1-4 alkyl, C1-4 alkoxy, C1-6 acyloxy, arom. acyloxy, OH, trialkyl, C1-4 acylamino, alkoxyalkoxy, alkoxyacyloxy, and trialkylsilyloxy; R3 = H, Me, cyano), useful for the treatment of breast cancer, are prepd. Thus, 2-bromo-6-methoxynaphthalene was treated with BuLi in hexane and THF at

L6 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
-78.degree. followed reaction with a soln. of p-cyanobenzaldehyde in THF at -78.degree. gave p-cyano-.alpha.-(6-methoxynaphthalen-2-yl)benzyl alc. which was stirred with SOCl2 in CH2Cl2 at room temp. for 1 h to give p-cyano-.alpha.-(6-methoxynaphthalen-2-yl)benzyl chloride. The latter chloride was dissolved in MeCN and refluxed with imidazole overnight to give, after silica gel chromatog. and acidification with HCl, title compd. (II.HCl) which in vitro showed IC50 of 3.7 nM against aromatase. Hard capsule, tablet, injection and suspension formulations contg. (p-cyanobenzyl)tetrazole deriv. (III.HCl) were described.

IT **162573-42-4P 162573-46-8P 162573-58-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (cyanobenzyl)azole deriv. as aromatase inhibitor and anticancer agent for breast cancer)

RN 162573-42-4 CAPLUS
CN Benzonitrile, 4-(1H-imidazol-4-yl-2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 162573-46-8 CAPLUS
CN Benzonitrile, 4-(1H-imidazol-4-yl-9-phenanthrenylmethyl)- (9CI) (CA INDEX NAME)



RN 162573-58-2 CAPLUS
CN Benzonitrile, 4-(1H-imidazol-4-yl-2-naphthalenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

L6 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:534112 CAPLUS
DOCUMENT NUMBER: 121:134112
TITLE: Preparation of imidazolylmethylenetetralones and analogs as aromatase inhibitors
INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton
PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940414	WO 1993-JP1433	19931006
W: AU, BB, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPLN. INFO.:			JP 1992-267130 A	19921006
			WO 1993-JP1433 W	19931006

OTHER SOURCE(S): MARPAT 121:134112
GI



AB The title compds. I [R represents hydrogen, C1-C4 lower alkoxy, nitro or C1-C4 lower alkoxycarbonyl; when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, Z represents hydrogen and the broken line represents an arbitrary bond; when X represents hydrogen, Y and Z are combined together to represent a single bond; n represents an integer of 0 or 1] are prepd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H2SO4 was heated for 20 h at 80-90.degree. to give, after workup, (E)-2-(4-imidazolylmethylene)-1-tetralone (II). II in vitro showed IC50 of 0.260 .mu.M against aromatase.

IT **157058-44-1P 157058-45-2P 157058-46-3P**
157058-47-4P 157058-52-1P 157058-53-2P
157058-54-3P 157058-55-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as aromatase inhibitor)

RN 157058-44-1 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 157058-45-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 157058-46-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]-

L6 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 157058-54-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 150559-29-8 CAPLUS
CN Acetic acid, [[6-[[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl]-5,6,7,8-
tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:671157 CAPLUS
DOCUMENT NUMBER: 119:271157
TITLE: Fused benzeneoxyacetic acid derivative PGI2 receptor agonists
INVENTOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Tokumoto, Hidekado
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 110 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 548949	A2	19930630	EP 1992-121898	19921223
EP 548949	A3	19931006		
EP 548949	B1	19970917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 05178832	A2	19930720	JP 1991-360502	19911227
JP 07025854	A2	19950127	JP 1992-209587	19920714
US 5461045	A	19951024	US 1992-912999	19920714
CA 2073917	AA	19940116	CA 1992-2073917	19920715
CA 2085844	AA	19930628	CA 1992-2085844	19921218
AT 158282	E	19971015	AT 1992-121898	19921223
ES 2108076	T3	19971216	ES 1992-121898	19921223
US 5389666	A	19950214	US 1992-997492	19921228
JP 07145057	A2	19950606	JP 1992-360608	19921228
JP 3419009	B2	20030623		
US 5589496	A	19961231	US 1994-334395	19941103
US 5849919	A	19981215	US 1996-722456	19960927
US 5962439	A	19991005	US 1998-168424	19981007

PRIORITY APPLN. INFO.: JP 1991-360502 A 19911227
JP 1992-209587 A 19920714
US 1992-997492 A3 19921228
US 1994-334395 A3 19941103
US 1996-722456 A3 19960927
OTHER SOURCE(S): MARPAT 119:271157
GI For diagram(s), see printed CA Issue.
AB The title compds. I [A = (un)substituted heterocyclyl; B = alkylene, alkenylene; ring D = carbocyclic ring; R1 = HO, C1-12 alkoxy, (un)substituted amino], which demonstrate PGI2 receptor agonist activity and are useful in the treatment of thrombosis, arteriosclerosis, ischemic heart diseases, gastric ulcer, or hypertension (no data), are prepd. and I-contg. formulations presented. Thus, pyrazole deriv. II was prepd. which demonstrated 50% inhibitory concn. against human blood platelet aggregation of 0.043 .mu.M in human blood-derived. platelet-rich plasma.
IT **150558-87-5 150559-29-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(PGI2 receptor agonist activity of)
RN 150558-87-5 CAPLUS
CN Acetic acid, [[5,6,7,8-tetrahydro-6-(1H-imidazol-4-ylmethyl)-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)

L6 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1993:649949 CAPLUS
DOCUMENT NUMBER: 119:249949
TITLE: Preparation of imidazole derivatives as interleukin 1 inhibitors and antiphlogistics
INVENTOR(S): Ueno, Yoshihide; Masumori, Hiroaki; Saji, Kitaro
PATENT ASSIGNEE(S): Sumitomo Pharma, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05155882	A2	19930622	JP 1991-348294	19911203

PRIORITY APPLN. INFO.: JP 1991-348294 19911203
OTHER SOURCE(S): MARPAT 119:249949
GI For diagram(s), see printed CA Issue.
AB The title derivs. I [A = lower alkylene; M = arom. hydrocarbon ring, thiophene; D = O, CO, CH(OR5), C(:NOR5), CH[N(R5)2], NR5, single bond; R1 = H, halo; R2 = lower alkyl or alkenyl, (un)substituted Ph, (un)substituted cycloalkyl, (un)substituted thienyl; R3 = N-contg. heterocyclyl; R4, R5 = H, lower alkyl; when D is single bond then R2 is lower alkoky] or their acid salts are prepd. as interleukin 1 inhibitors and antiphlogistics. A mixt. of 3-(2-fluoro-4-biphenyl)-1-(4-pyridylcarbonyl)amino-2-butanone (prepd. from fluorobiprofen in 4 steps), and NH4Ac was heated at 140-150.degree. for 4 h to give 44% 4-(1-(2-fluoro-4-biphenyl)ethyl)-2-(4-pyridyl)imidazole-HCl. I inhibited growth of interleukin 1.
IT **150972-40-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as interleukin 1 inhibitor and antiphlogistics)
RN 150972-40-0 CAPLUS
CN 2-Naphthalenol, 6-[1-[2-(4-pyridinyl)-1H-imidazol-4-yl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L6 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:106173 CAPLUS
DOCUMENT NUMBER: 116:106173
TITLE: Synthesis and .alpha.-adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs
AUTHOR(S): Amemiya, Yoshiya; Hong, Seoung S.; Venkataraman, Burrah V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl; Feller, Dennis R.; Hsu, Fu Lian; Miller, Duane D.
CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
SOURCE: Journal of Medicinal Chemistry (1992), 35(4), 750-5
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Analogs I-III (R = 1-naphthyl, 2-naphthyl; R1 = H, Me) of medetomidine and naphazoline were synthesized and evaluated for their .alpha.1 (aorta) and .alpha.2 (platelet) activities. In general the 1-naphthalene analogs were the most potent inhibitors of epinephrine-induced platelet aggregation. Of considerable interest was the fact that I-III (R = 1-naphthyl) were antagonists in an .alpha.1-adrenergic system (aorta). Thus, appropriately substituted naphthalene analogs of medetomidine and naphazoline provide a spectrum of .alpha.1-agonist, .alpha.1-antagonist, and .alpha.2-antagonist activity.
IT **137967-82-9P 137967-88-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and adrenergic activity of)
RN 137967-82-9 CAPLUS
CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 137967-88-5 CAPLUS
CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1992:15364 CAPLUS
DOCUMENT NUMBER: 116:15364
TITLE: Structure-activity studies of new imidazolines on adrenoceptors of rat aorta and human platelets
AUTHOR(S): Venkataraman, B. V.; Shams, G.; Hamada, A.; Amemiya, Y.; Tantishaiyakul, V.; Hsu, F.; Fashempour, J.; Romstedt, K. J.; Miller, D. D.; et al.
CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1991), 344(4), 454-63
CODEN: NSAPCC; ISSN: 0028-1298
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Potencies of new arom. substituted fluoro or iodo analogs of catecholimidazoline (I) on functional responses in rat aorta (.alpha.1) and platelets (.alpha.2) were quantified. When compared either on the basis of EC50 or the dissocn. const. (KA), 5-fluorocatecholimidazoline was as potent as the ref. .alpha.1-adrenoceptor agonist, phenylephrine in the vascular tissue. The max. contraction of aorta produced by the fluoro analog was, however, 17% higher than that of phenylephrine. The time required for 1/2 relaxation of the tissue after 5-fluoro hydroxy imidazoline was at least twice as long as that of the phenylephrine. The catechol moiety as well as fluorine substitution at the crit. 5-position of the arom. ring is essential for higher .alpha.1 adrenoceptor-mediated potency. As compared to the fluoro analogs, the adrenoceptor-mediated potencies of iodo-analogs were relatively weak on vascular tissue. Naphazoline and its analogs were partial agonists on vascular tissue with dissocn. consts. which ranged from 110 to 2600 nmol/L. Imidazole analogs (II, R = naphthyl or xylene), were generally less potent agonist than the imidazolines by one order of magnitude. The vascular effects of all agonists were competitively blocked by prazosin with KB values which ranged from 0.04 to 0.48 nmol/L. Since the variation in KB values were within normal limits, the action of new imidazolines on rat aorta appears to be mediated mainly by the activation of the .alpha.1-adrenoceptor. Prazosin 10 nmol/L abolished the vascular response of some partial agonists. This indicates a slightly different mode of interaction of agonists with the transduction process. Carbon 4-substituted imidazolines produced little or no .alpha.1 adrenoceptor-mediated intrinsic activity, but competitive receptor blocking potency was comparable to that of phentolamine. Medetomidine was a partial agonist on the rat aorta with a KA of 260 nmol/L. When investigated as a blocker, the KB of medetomidine against phenylephrine was approx. 5600 nmol/L. The variation in the latter value was high. In acetylsalicylic acid-treated human platelets, the .alpha.2-adrenoceptor-mediated aggregatory effect of all fluoro analogs was weak. Iodo or naphazoline analogs did not initiate platelet

L6 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
aggregation but blocked the aggregation induced by epinephrine. The affinity of naphazoline for the .alpha.2-adrenoceptor was 1100 nmol/L. The IC50 of medetomidine for platelet anti-aggregatory effect was 3300 nmol/L, which compares favorably with other imidazoline type of blockers of platelet aggregations. Sympathomimetic vasoconstrictor actions and platelet aggregation effects of these compds. can be dissocd. Some vasoconstrictors were antiaggregatory. The structure-activity relationships of the two receptor systems, namely rat aorta (.alpha.1) and platelets (.alpha.2), are discussed.
IT **137967-88-5**
RL: BIOL (Biological study)
(.alpha.-adrenoceptors of aorta and human platelets interaction with, structure in relation to)
RN 137967-88-5 CAPLUS
CN 1H-Imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1991:623482 CAPLUS
DOCUMENT NUMBER: 115:223482
TITLE: Use of 5-HT3 receptor antagonists for treatment of panic disorders, agoraphobia, or obsessive compulsive disorders
INVENTOR(S): Azcona, Alberto
PATENT ASSIGNEE(S): Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H., Austria; Sandoz-Patent-G.m.b.H.; Sandoz A.-G.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9012569	A1	19901101	WO 1990-EP540	19900406
W: AU, CA, JP, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2031214	AA	19901022	CA 1990-2031214	19900406
AU 9054158	A1	19901116	AU 1990-54158	19900406
AU 631632	B2	19921203		
EP 422154	A1	19910417	EP 1990-905482	19900406
EP 422154	B1	19931201		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 03505881	T2	19911219	JP 1990-505770	19900406
JP 06069963	B4	19940907		
AT 97803	E	19931215	AT 1990-905482	19900406
ES 2061024	T3	19941201	ES 1990-905482	19900406
ZA 9003015	A	19911224	ZA 1990-3015	19900420
US 5530008	A	19960625	US 1994-187413	19940124

PRIORITY APPLN. INFO.:
GB 1989-9147 19890421
GB 1989-16602 19890720
EP 1990-905482 19900406
WO 1990-EP540 19900406
US 1990-635156 19901219

AB 5-HT3 receptor antagonists are useful in treating panic disorders and/or agoraphobia or obsessive compulsive disorders. Formulations for tablets, i.v. solns. and capsules are presented.
IT **135716-73-3**
RL: BIOL (Biological study)
(5-HT3 receptor antagonist)
RN 135716-73-3 CAPLUS
CN 1(2H)-Phenanthrenone, 3,4-dihydro-2-[(5-methyl-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:198377 CAPLUS
DOCUMENT NUMBER: 112:198377
TITLE: Preparation and formulation of imidazole derivatives as 5-HT3 receptor antagonists
INVENTOR(S): North, Peter Charles; Oxford, Alexander William; Coates, Ian Harold
PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
SOURCE: Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 336759	A1	19891011	EP 1989-303415	19890406
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 02049772	A2	19900220	JP 1989-87841	19890406
US 5116984	A	19920526	US 1989-333967	19890406

PRIORITY APPLN. INFO.:
GB 1988-8085 19880407
GB 1988-8086 19880407

OTHER SOURCE(S): MARPAT 112:198377
GI



I

AB Title compds. I (R1,R2 = H, halo, HO, C1-4 alkoxy, C1-4 alkyl, C1-4 alkylthio, R3R4N, R3, R4 = H, C1-4 alkyl, R3R4N = satd. 5-7-membered ring; A = CH, N; Im = substituted imidazolyl; n = 1-3) and physiol. acceptable salts and solvates thereof, potent and selective antagonists of 5-HT3 receptors and useful, e.g., in treatment of psychotic disorders, anxiety, and nausea and vomiting (no data), are prepd. 1,2-Dihydro-3-[[5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]methylene]-4(3H)-phenanthrenone (prepn given) was dehydrogenated over Pd/C to give I (R1, R2 = H; A = CH; Im = 5-methylimidazol-4-yl; n = 2) which was converted to the maleate. Tablet and injection formulations were given.
IT **126737-68-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as 5-HT antagonist)
RN 126737-68-6 CAPLUS
CN 4(1H)-Phenanthrenone, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 126737-65-3
CMF C19 H18 N2 O



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT **126737-65-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as HT3-receptor antagonist)
RN 126737-65-3 CAPLUS
CN 4(1H)-Phenanthrenone, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1990:139033 CAPLUS
DOCUMENT NUMBER: 112:139033
TITLE: Preparation of imidazole derivatives as drugs
INVENTOR(S): Kihara, Noriaki; Tomino, Ikuo; Tan, Hiroaki; Takei, Mitsusachi
PATENT ASSIGNEE(S): Mitsui Petrochemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01242571	A2	19890927	JP 1988-65731	19880322

PRIORITY APPLN. INFO.: JP 1988-65731 19880322
OTHER SOURCE(S): MARPAT 112:139033
GI



I

II



III



IV



V

AB The title derivs. I or II (R1 = H, Ph; R2-R5 = H, OH, lower alkyl, lower alkoxy, lower alkylamino, halo; R2-R5 may be bonded to from rings; R6, R7 = H, lower alkyl, halo; X = O, S), useful as cerebral function improvers, antihypertensives, diuretics, etc. (no data), are prepd. by acid-catalyzed reaction of (hydroxymethyl)imidazoles III or their acid salts with benzenes IV or 5-membered heterocycle V. Thus, aq. III.HCl (R1 = H) was treated with 1,3,5-C6H3Me3 and 4-MeC6H4SO3H at 170.degree. for 7 h to give 76% I (R1 = R2 = H, R3-R5 = 2,4,6-Me3).

IT **125883-69-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as drug)

RN 125883-69-4 CAPLUS
CN 1H-Imidazole, 4-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L6 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1979:168771 CAPLUS
DOCUMENT NUMBER: 90:168771
TITLE: Photochemical reactions. Photochemistry of N-acylimidazoles. V. Photolysis of the N-acylimidazoles of dehydroabietic acid and of 13-deisopropyl-10-epi-dehydroabietic acid
AUTHOR(S): Iwasaki, Shigeo
CORPORATE SOURCE: Org.-Chem. Lab., ETH, Zurich, Switz.
SOURCE: Helvetica Chimica Acta (1978), 61(8), 2843-50
CODEN: HCACAV; ISSN: 0018-019X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III



IV

AB Irradn. of I gave no Type II elimination, but gave II and III by migration of the imidazolylcarbonyl group, probably via a cyclobutanol intermediate. Similarly, irradn. of IV gave only a small amt. of Type II fragmentation, the main products being derived from .gamma.-H abstraction.

IT **69634-29-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 69634-29-3 CAPLUS
CN Methanone, 1H-imidazol-4-yl[4b,5,6,7,8,8a,9,10-octahydro-4b,8-dimethyl-2-(1-methylethyl)-9-phenanthrenyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L6 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1973:515495 CAPLUS
DOCUMENT NUMBER: 79:115495
TITLE: Synthesis of small molecule catalysts. Model for the active site of ribonuclease-A
AUTHOR(S): Algieri, Aldo A.
CORPORATE SOURCE: Cornell Univ., Ithaca, NY, USA
SOURCE: (1973) 116 pp. Avail.: Univ. Microfilms, Ann Arbor, Mich., Order No. 73-14,715
From: Diss. Abstr. Int. B 1973, 33(12)(Pt. 1), 5722
DOCUMENT TYPE: Dissertation
LANGUAGE: English
AB Unavailable
IT **49738-45-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(as model for the active site of ribonuclease A)
RN 49738-45-6 CAPLUS
CN 1H-Imidazole-4-ethanamine, N-[[3-(1H-imidazol-4-ylmethyl)-1-naphthalenyl]methyl]-, conjugate diacid (9CI) (CA INDEX NAME)



●2 H+

L6 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1972:501463 CAPLUS
DOCUMENT NUMBER: 77:101463
TITLE: Voges-Proskauer reaction. II. Structure of a pigment from the diacetyl reaction of 1-benzyl-1-methylguanidine
AUTHOR(S): Nishimura, Tamio; Yamazaki, Chiji; Ueno, Tetsuro; Kitajima, Shinichi; Ishige, Koichi
CORPORATE SOURCE: Sch. Hyg. Sci., Kitasato Univ., Tokyo, Japan
SOURCE: Bulletin of the Chemical Society of Japan (1972), 45(6), 1782-5
CODEN: BCSJA8; ISSN: 0009-2673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A pigment formed by the reaction of 1-benzyl-1-methylguanidine was isolated as reddish purple prisms. The reduced pigment was colorless and rapidly converted back to the original pigment on exposure to the air. On the basis of ir, NMR, and mass spectral evidence, the structures of the pigment and the reduced form were established to be 2-(N-benzyl-N-methylamino)-4-methyl-5-(1-oxo-1,2-dihydro-2-naphthylidenemethyl)imidazole and 5-(1-hydroxy-2-naphthylmethyl)imidazole, resp.
IT **37842-56-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 37842-56-1 CAPLUS
CN 1-Naphthalenol, 2-[[5-methyl-2-[methyl(phenylmethyl)amino]-1H-imidazol-4-yl]methyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.62	338.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-22.18	-22.18

STN INTERNATIONAL LOGOFF AT 08:01:11 ON 13 JAN 2004